Amneal Pharmaceuticals Inc (AMRX)
8.245
-0.16
(-1.85%)
USD |
NASDAQ |
Nov 05, 16:00
8.25
0.00 (0.00%)
After-Hours: 19:17
Amneal Pharmaceuticals Revenue (Quarterly): 701.78M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 701.78M |
| March 31, 2024 | 659.19M |
| December 31, 2023 | 616.98M |
| September 30, 2023 | 620.04M |
| June 30, 2023 | 599.05M |
| March 31, 2023 | 557.54M |
| December 31, 2022 | 609.76M |
| September 30, 2022 | 545.56M |
| June 30, 2022 | 559.36M |
| March 31, 2022 | 497.63M |
| December 31, 2021 | 536.90M |
| September 30, 2021 | 528.59M |
| June 30, 2021 | 535.08M |
| March 31, 2021 | 493.10M |
| December 31, 2020 | 510.03M |
| Date | Value |
|---|---|
| September 30, 2020 | 519.29M |
| June 30, 2020 | 464.66M |
| March 31, 2020 | 498.53M |
| December 31, 2019 | 397.33M |
| September 30, 2019 | 378.28M |
| June 30, 2019 | 404.64M |
| March 31, 2019 | 446.12M |
| December 31, 2018 | 497.53M |
| September 30, 2018 | 476.49M |
| June 30, 2018 | 413.79M |
| March 31, 2018 | 275.19M |
| December 31, 2017 | 293.37M |
| September 30, 2017 | 254.73M |
| June 30, 2017 | 259.87M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
397.33M
Minimum
Dec 2019
701.78M
Maximum
Jun 2024
550.02M
Average
536.90M
Median
Dec 2021
Revenue (Quarterly) Benchmarks
| Eli Lilly and Co | 11.44B |
| Nutriband Inc | 0.4428M |
| NovaBay Pharmaceuticals Inc | 2.40M |
| Palatin Technologies Inc | 0.35M |
| iBio Inc | 0.175M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 5.994M |
| Total Expenses (Quarterly) | 618.84M |
| EPS Diluted (Quarterly) | 0.02 |
| Enterprise Value | 5.223B |
| Gross Profit Margin (Quarterly) | 35.62% |
| Profit Margin (Quarterly) | 0.85% |
| Earnings Yield | -7.52% |
| Operating Earnings Yield | 13.07% |
| Normalized Earnings Yield | -3.488 |